• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » antipsychotics

Articles Tagged with ''antipsychotics''

Glutamate’s Role in Schizophrenia

March 1, 2014
Steve Balt, MD, MS
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Steve Balt, MD, MS Board Member, The Carlat Report. In private practice in the San Francisco Bay area. Dr. Balt discloses that his spouse is employed as a sales representative for Otsuka America.
There’s a rich history of research suggesting that glutamate may be involved in the pathogenesis of schizophrenia, with an increasing amount of attention being brought to glutamate during the past decade or so.
Read More

Lower Antipsychotic Use Linked to Better Outcomes

October 30, 2013
Section editor, Glen Spielmans, PhD
...
Read More

APA Warns Against Common Uses of Antipsychotics

October 1, 2013
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
In September, the American Psychiatric Association (APA) released a list of common, but potentially dangerous and inappropriate, uses for antipsychotics.
Read More
RESEARCH UPDATE

Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

September 1, 2013
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Section editor, Glen Spielmans, PhD

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

What’s the optimal treatment for a first episode of psychosis? Few would argue against antipsychotic treatment, but what happens when the patient achieves remission?
Read More

The Psychosis Prodrome

January 1, 2013
Rachel Loewy, PhD and Demian Rose, PhD, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Rachel Loewy, PhD Assistant adjunct professor, University of California, San Francisco Dr. Loewy has disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to this educational activity. Demian Rose, PhD, MD Assistant clinical professor, University of California, San Francisco Dr. Rose hase disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
At the crossroads of these experiences lies the concept of the psychosis prodrome and early intervention/prevention efforts. But without evidence of a florid psychotic episode, when should one intervene?
Read More

Atypical Antipsychotics: Where is the Science, Where is the Evidence?

January 1, 2013
P Ken Gillman, MBBS
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
P Ken Gillman, MBBS Director, Psychotropical (www.psychotropical.com), Bucasia, Queensland, Australia Dr. Gillman has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Any psychiatrist who has practiced during the last decade has probably written more than a few prescriptions for an atypical antipsychotic. But do these drugs provide any clear advantages over their predecessors?
Read More

Old Versus New Antipsychotics

January 1, 2013
Robert Rosenheck, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Robert Rosenheck, MD Professor of Psychiatry, Epidemiology and Public Health, and the Child Study Center, Yale Medical School Dr Rosenheck has disclosed he received research support from Pfizer Pharmaceuticals to analyze CATIE data and has served as a consultant to Otsuka Pharmaceuticals on a long acting injectable antipsychotic. Dr. Balt has reviewed this article and found no evidence of bias in this educational activity.
Are the benefits of atypical antipsychotics based in reality? Dr. Rosenheck explains the stark difference between the SGAs of pharmaceutical myth and what has been proven with actual science.
Read More

Some Popular Antipsychotics May Not be Effective in Patients over 40

January 1, 2013
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
  Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.
Atypical antipsychotics are widely prescribed for a number of psychiatric diagnoses, but their real-world effectiveness has rarely been evaluated in anything other than short-term trials. A recently published study finds that four commonly used antipsychotics (aripiprazole [Abilify], olanzapine [Zyprexa], quetiapine [Seroquel], and risperidone [Risperdal]), when used in patients over age 40 with schizophrenia or psychosis associated with other conditions, may not be effective—and cause frequent side effects.
Read More

The Psychopharmacology of Anxiety Treatment in Children and Adolescents

December 1, 2011
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Caroline Fisher, PhD, MD
Anxiety disorders are common in young people, affecting 4%–7% of children. It appears that the majority of “adult” anxiety disorders begin in childhood and are stable and often chronic conditions, so an effective intervention can have lifelong benefits.
Read More

Effective Psychotherapies for Childhood Anxiety

December 1, 2011
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Sara Brewer, MD
While there are many different anxiety disorders, the mainstay of treatment for nearly all of them is the same: cognitive behavioral therapy (CBT).
Read More
Previous 1 2 … 8 9 10 11 12 13 14 15 16 17 18 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2639254965.jpg
    General Psychiatry

    Psychopharm Secrets: Starting Meds

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.